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Available online 09 February 2017Slc17a5−/−mice represent an animal model for the infantile form of sialic acid storage disease (SASD). We ana-
lyzed genetic and histological time-course expression ofmyelin and oligodendrocyte (OL) lineagemarkers in dif-
ferent parts of the CNS, and related this to postnatal neurobehavioral development in thesemice. Sialin-deﬁcient
mice display a distinct spatiotemporal pattern of sialic acid storage, CNS hypomyelination and
leukoencephalopathy. Whereas few genes are differentially expressed in the perinatal stage (p0), microarray
analysis revealed increased differential gene expression in later postnatal stages (p10–p18). This included pro-
gressive upregulation of neuroinﬂammatory genes, as well as continuous down-regulation of genes that encode
myelin constituents and typical OL lineage markers. Age-related histopathological analysis indicates that initial
myelination occurs normally in hindbrain regions, but progression to more frontal areas is affected in
Slc17a5−/−mice. This course of progressive leukoencephalopathy and CNS hypomyelination delays neurobehav-
ioral development in sialin-deﬁcient mice. Slc17a5−/− mice successfully achieve early neurobehavioral mile-
stones, but exhibit progressive delay of later-stage sensory and motor milestones. The present ﬁndings may
contribute to further understanding of the processes of CNS myelination as well as help to develop therapeutic
strategies for SASD and other myelination disorders.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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107S. Stroobants et al. / Experimental Neurology 291 (2017) 106–119of SASD at either end of the disease spectrum. Children suffering
from ISSD present with severe neurodevelopmental defects that rapidly
deteriorate, leading to early death. Salla disease does involve psycho-
motor and cognitive disability, but patients experience a slower deteri-
oration than ISSD patients and survive into adulthood (Haataja et al.,
1994).
Myelination defects occur in clinical SASD as well as in mice with
sialin deﬁciency (Prolo et al., 2009), but little is known about their pro-
gression and pathological concomitants. SASD leads to progressive cer-
ebellar atrophy as well as decreased cerebral white matter volume,
whichhavebeen suggested to be caused by hypomyelination (i.e., insuf-
ﬁcientmyelin deposition and/ormaturation), rather thanmyelin break-
down (Haataja et al., 1994; Sonninen et al., 1999; Varho et al., 2000;
Parazzini et al., 2003;Morse et al., 2005; Steenweg et al., 2010). The pro-
cess of myelination comprises a sequence of intricate developmental
events that start by oligodendrocyte progenitors (OPs) proliferating in
the ventral part of the embryonic neural tube (Baumann and
Pham-Dinh, 2001; Miller, 2002; Miller, 2005; Kessaris et al., 2006;
Bercury and Macklin, 2015). These OPs subsequently migrate dorsally
and rostrally throughout the forebrain and spinal cord, contact axons,
and differentiate into myelin-forming oligodendrocytes (OLs). The OL
lineage is generally divided into four stages: early OPs,
preoligodendrocytes or late OPs, immature OL and mature OL. Craig et
al. (2003) studied the analogy of human and rodent OL lineage progres-
sion. Their quantiﬁcation of these events in rodents revealed that cere-
bral white matter mainly contains late OPs at postnatal day 2 (p2),
whereas immature OLs remain a minority (Craig et al., 2003). Later
(around p7), immature OLs become the majority and initiate
myelination.
Sialin-deﬁcient mice were generated to study the pathophysio-
logical mechanisms of clinical SASD (Prolo et al., 2009; Moechars
et al., 2005). Sialin deﬁciency was indeed shown to cause
hypomyelination in these mice, which was attributed to defective
OL lineage maturation, leading to cell death and functional defects.
Clinical SASD studies showed that functional capacities of patients
were related to their levels of residual sialin activity (Wreden et al.,
2005; Ruivo et al., 2008). In the present report, we further detailed
the various histopathological features of postnatal progressive
leukoencephalopathy in sialin-deﬁcient mice, and assessed their
functional consequences. Genetic and histological time-courseFig. 1. Biochemical characteristics of sialin-deﬁcient mice. (A) Concentration of free sialic acid in
mouse (KO). For comparison free sialic acid was also measured in human skin ﬁbroblasts from
and Salla (SAL) type. (B) Transport activity of sialin inpuriﬁed lysosomalmembrane vesicles ofm
Activity was measured in the presence (+) and in the absence (−) of a proton gradient. As
mean + SEM.expression of myelin, OL lineage and other pathogenically relevant
markers was examined during postnatal brain development. Finally,
we identiﬁed milestones of neurobehavioral development in mouse
pups to document potential developmental disabilities caused by their
sialin deﬁciency. Our results provide new insights on the pathophysio-
logical mechanisms of SASD hypomyelination and could contribute to
therapeutic strategies in these and more common myelination
disorders.
2. Results
2.1. Slc17a5−/− mice show a progressive disease course and premature
mortality
The Slc17a5−/−mice were ﬁrst presented in 2005 (Moechars et al.,
2005) and have been previously characterized (Prolo et al., 2009). Our
qualitative observations of these mice have been consistent with their
published phenotype i.e. they experience growth delays, making them
smaller than equivalently aged controls, and they had a severely re-
duced lifespan.2.2. Slc17a5−/−mice show free sialic acid accumulation and defective lyso-
somal transport
SASD results from defective clearance of free sialic acid out of the ly-
sosome via the lysosomal transport protein sialin. To determine the
level to which Slc17a5−/− mice mimic biochemical characteristics of
clinical SASD, the amount of free sialic acid in embryonic ﬁbroblasts of
Slc17a5+/+, Slc17a5+/− and Slc17a5−/−mice was ﬁrst compared with
diagnostic values of cultured ﬁbroblasts of all clinical variants of SASD
patients (ISSD, intermediate SASD and Salla disease; Fig. 1A).
Slc17a5−/−mice showed an accumulation of free sialic acid (66 nmol/-
mg protein) in ﬁbroblast homogenates, exceeding themost severe clin-
ical phenotype ISSD (30 nmol/mg protein).
Next, we conﬁrmed that these elevated levels could indeed be linked
to defective sialin-mediated lysosomal clearance. Proton-gradient me-
diated transport, featuring tritiated glucuronic acid as a sialin substrate,
was assessed using puriﬁed lysosomalmembrane vesicles from livers of
rat (RLV), Slc17a5+/+, Slc17a5+/− and Slc17a5−/− mice. Increasedcultured ﬁbroblasts of Slc17a5+/+mouse (WT), Slc17a5+/−mouse (HET) and Slc17a5−/−
controls (CON) and the three clinical variants of SASD, infantile (ISSD), intermediate (INT)
ouse livers. Uptake of radiolabeled glucuronic acid inWT, HET andKOmicewas evaluated.
reference, activity was also measured in rat liver vesicles (RLV). Data are presented as
108 S. Stroobants et al. / Experimental Neurology 291 (2017) 106–119uptake of glucuronic acid was observed in rat as well as Slc17a5+/+ and
Slc17a5+/−mouse vesicles upon acidiﬁcation of the environment (+)
(Mancini et al., 1989). However, lysosomal vesicles prepared fromFig. 2. Lysosomal vacuolization of CNS cells in sialin-deﬁcient mice. CNS cells of Slc17a5+/+ mi
staining: cytoplasmic vacuolization in CA1 hippocampal neurons (B), ependymal cells of third
Slc17a5+/+ mice (A, C, E). G–H: LAMP-1 immunohistochemistry (brown) of hippocampus de
(G); Slc17a5−/− mice show irregularly shaped, prominent vacuoles positive for LAMP-1 (H:
and Slc17a5−/− mice (J). Arrow: vacuolization of cytoplasm in GFAP-immunoreactive astr
references to color in this ﬁgure legend, the reader is referred to the web version of this articleSlc17a5−/−mice showed completed absence of increased substrate-up-
take (− versus +), conﬁrming defective lysosomal transport through
sialin (Fig. 1B).ce (WT, left panel) and Slc17a5−/−mice (KO, right panel) at p18. A–F: Hematoxylin-eosin
ventricle (D) and Purkinje cells in cerebellum (F) of Slc17a5−/−mice, in comparison to
ntate gyrus (DG) and CA-3 neurons: Slc17a5+/+ mice show granular, punctate staining
arrow). I–J: GFAP-immunohistochemistry (red) on hippocampus of Slc17a5+/+ mice (I)
o-glial cell. Scale bars (A–D): 20 μm and (E–H, I–J): 50 μm. (For interpretation of the
.)
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and peripheral tissues
Intralysosomal substrate accumulation induces vacuolization in
affected cells, which constitutes a typical neuropathological hall-
mark of human SASD as well as other lysosomal storage disorders.
We investigated lysosomal storage pathology in several central and
peripheral tissues. Indeed, the most prominent morphological differ-
ence observed in different types of cells (e.g.: neurons, glial cells,
ependymal cells) between Slc17a5+/+ and Slc17a5−/− mice (p18)
throughout the entire nervous system was cytoplasmic vacuolization
(Fig. 2).
Vacuolization was observed in neuronal and non-neuronal CNS cells
of Slc17a5−/−mice, such as hippocampal neurons (Fig. 2B), ependymal
cells (Fig. 2D), cerebellar Purkinje cells (Fig. 2F), spinal cord neurons
(not shown) and astroglial cells (Fig. 2J). This was in contrast to respec-
tive CNS cells of Slc17a5+/+ mice (Fig. 2A,C,E,I). LAMP-1 immunohisto-
chemistry conﬁrmed that these vacuolar structures are likely derived
from lysosomes and/or late endosomes. LAMP-1 immunoreactivity in
CA3 and dentate gyrus (DG) neurons shows a granular, punctate, dis-
tinct pattern in brain of Slc17a5+/+ mice (Fig. 2G), whereas
Slc17a5−/−mice show irregularly shaped, prominent vacuoles, strongly
positive for LAMP-1 (Fig. 2H). Similar to CNS cells, cytoplasmic
vacuolization was observed in Schwann cells of the ischiadic nerve in
Slc17a5−/−mice, which however showed normal myelination (Fig. 3).
Other peripheral tissue such as liver (Fig. 4B), endo-/exocrine pancreas
(Fig. 4E, F) and gastro-intestinal mucosa and plexus (Fig. 4H, J) also
showed signs of vacuolization in Slc17a5−/−mice. Histological evidence
for neuroinﬂammationwas observed in occurrence of reactive gliosis in
the hippocampal ﬁssure and external capsule of 3 of 5 investigated
Slc17a5−/− brains at p18, as revealed by GFAP-immunoﬂuorescence
(data not shown). The GFAP-immunoreactivity appeared to be denser
in Slc17a5−/− mice, for which however no quantiﬁcation was per-
formed. In general, the average number of neurons in randomly selected
areas (0.096 mm2 per area) of cerebral cortex and of Purkinje cells in
randomly selected areas (0.096 mm2 per area) of cerebellum did not
differ signiﬁcantly (p = 0.52 for cortical neuronal density & p = 0.71
for Purkinje cell density) between Slc17a5+/+ (37.6 ± 1.8 and 23.2 ±
2 respectively) and Slc17a5−/− (38.4± 1.1 and 22.1± 2.7 respectively)
mice. On average 38.0 neurons and 22.7 Purkinje cells were counted per
high power microscopic ﬁeld (0.096 mm2).Fig. 3. Cytoplasmic vacuolization but normal myelination in the PNS of sialin-deﬁcient mice. To
peripheral nerve ﬁbers of Slc17a5+/+ mice (WT, A) and of Slc17a5−/−mice (KO, B) have a sim
contain cytoplasmic vacuoles whereas this was not observed in Schwann cells of peripheral ner
to color in this ﬁgure legend, the reader is referred to the web version of this article.)2.4. Slc17a5−/−mice show progressive differential gene expression related
to lysosomal dysfunction, neuroinﬂammation and hypomyelination during
postnatal brain development
Microarray analysis was performed on total brain RNA isolated from
Slc17a5−/−mice and Slc17a5+/+ controls at p0, p10 and p18. This com-
parison was done to investigate the performance of different genes in-
volved during postnatal brain development, providing further insight
in pathogenic processes in SASD. Speciﬁc time points were chosen to in-
clude evaluation before and after onset of clinical observations. The
pathways where differential gene expression is observed between ge-
notypes are illustrated in function of time (Fig. 5). Expression of
Slc17a5 was found to be clearly down regulated in the Slc17a5−/−
mice, conﬁrming the knock down. During development an increase in
the number of differently expressed genes was observed.
In brains of newborn Slc17a5+/+ versus Slc17a5−/− littermates (p0),
SAM analysis identiﬁed only 12 genes that were differentially
expressed, 7 ofwhichwere down regulated (including: Slc17a5 andmy-
elin basic protein (MBP)). Like many other genes involved in CNS
myelination, myelin regulatory factor (Myrf) was not differentially
expressed at p0. Furthermore, no differential expression was observed
for the platelet-derived growth factor-α (Pdgfra) and NG2 chondroitin
sulphate proteoglycan (Cspg4). These constitute two markers of the
early OP precursor cell, which is predominant at p0. Some
upregulated genes are related to neuroinﬂammatory response (macro-
phage expressed gene 1 (Mpeg1) and Fcgr2b), while others include ly-
sosomal enzymes cathepsin D and galactosylceramidase (Galc).
Upregulation of lysosomal and neuroinﬂammatory genes are therefore
among the earliest pronounced responses to sialin deﬁciency in
Slc17a5−/−mice.
SAM analysis (FDR b 0.005) on the microarray data of the brain of
Slc17a5−/−mice compared to Slc17a5+/+mice at p10 and p18 demon-
strated a substantial increase and striking overlap of differentially
expressed genes, albeit effects appeared more subtle at p10 (Fig. 5). At
p18, 378 genes were differentially expressed in brain samples of
Slc17a5+/+ versus Slc17a5−/− mice. Expression of 298 of them was
found to be downregulated in the brain of Slc17a5−/−mice compared
to Slc17a5+/+mice. Only 20% of the signiﬁcantly altered geneswere up-
regulated. Increased differential expression of several genes that encode
lysosomal enzymes and other lysosomal related proteinswas indicative
of lysosomal dysregulation in the brain of Slc17a5−/−mice. Amultitudeluidine blue staining of a longitudinal section of plastic embedded nervus ischiadicus. The
ilar number and thickness at p18. Schwann cells in nerve ﬁbers (arrow) of Slc17a5−/− (B)
ve ﬁbers from Slc17a5+/+mice (A). Scale bars: 50 μm. (For interpretation of the references
Fig. 4. Lysosomal vacuolization of different cell types in peripheral tissues in sialin-deﬁcient mice. Hematoxylin-eosin staining of peripheral tissues of Slc17a5+/+ mice (WT, left panel),
Slc17a5−/−mice (KO, right panel) at P18. Arrows indicate vacuolization which was observed in liver (B), endocrine pancreas (E), exocrine pancreas (F), gastric mucosa (H) and gastric
myenteric plexus (J) of Slc17a5−/−mice in contrast to corresponding peripheral tissues of Slc17a5+/+ mice (A,C,D,G,I).
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sponse with a notable increased presence of activated phagocytic mac-
rophages (Mpeg1). SAM analysis also identiﬁed other genes involved in
cholesterol and lipid biosynthesis to be differentially expressed in the
brain of Slc17a5−/− mice, mainly at reduced levels. Expression of
many known genes encoding constituents of myelin, the compactFig. 5. Genes encoding typical markers of the oligodendrocyte lineage are downregulated in si
main affected processes when comparing Slc17a5−/− to Slc17a5+/+ mice. The genes listed are
expression is shown as bars representing the log2ratios. Bars to the left represent genes down
4-fold change. Bars smaller than the grey background zone show b2-fold change.lamellar wrapping found on relative large ﬁber axons, was decreased.
Examples of these are MBP, myelin-associated oligodendrocytic basic
protein (Mopb), myelin-associated glycoprotein (Mag), cyclic nucleo-
tide phosphodiesterase 1 (Cnp1), proteolipid protein 1 (Plp1), and oli-
godendrocyte-myelin glycoprotein (Omg). Genes that encode typical
markers of OL lineage, the neural tube derived cells that form myelin,alin-deﬁcient mice. Gene expression analysis in mouse brain at p0, p10 and p18 showing
those that show at least 20% change for at least one of the three time points. Differential
regulated in Slc17a5−/−mice. Bars reaching the outer grey lines represent genes with N
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Fig. 6. Gradual decrease of CNS myelination from cerebellar to frontal regions in sialin-deﬁcient mice. MBP immunoﬂuorescence in CNS of Slc17a5+/+ (WT, left panel) and Slc17a5−/−
mouse brain (KO, right panel) at p18. A marked decrease and abnormal pattern of MBP staining in CNS of Slc17a5−/−mice is observed in coronal sections from frontal brain regions
(A2), midbrain (B2) and cerebellum (C2). The loss of myelin in white matter of Slc17a5−/− mouse brains is most pronounced in frontal and midbrain regions. High magniﬁcation
images of MBP immunoﬂuorescence (middle panels) from indicated areas of corpus callosum, cerebral cortex and cerebellum of Slc17a5+/+ (WT: A1a, B1a - A1b, B1b - C1a) and
Slc17a5−/− mouse brain (KO: A2a, B2a - A2b, B2b – C2a). Red: MBP-IF; blue: Hoechst nuclear counter stain. 4V: 4th ventricle, aca: anterior commissure, alv: alveus of the
hippocampus, av.: arbor vitae cerebellum, cc: corpus callosum, cg: cingulum, dc: dorsal cochlear nucleus, dg: dentate gyrus, ec: external capsule, ﬁ: ﬁmbria, ﬂ: ﬂocculus, icp: inferior
cerebellar peduncle, mt: mammilothalamic tract, py: pyramidal tract, sp5: spinal trigeminal tract, vcp: ventral cerebellar peduncle. Scale bars: 200 μm (high magniﬁcations), 2000 μm
(overviews). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Slc17a5−/− mice. Expression of Myrf, a transcription factor which di-
rectly regulates differentiation of OLs and their expression of myelin
genes was downregulated at p18. Apart from these markers, a wide va-
riety of genes expressed predominantly or exclusively in the OLs or re-
ported to be involved in myelin formation or OL function were also
found to be expressed at reduced levels in the brain of Slc17a5−/−
mice. The observed decreased expression of such a wide variety of OL
and myelin marker genes points to a strong reduction in the number
of mature OLs in the brain of the sialin-deﬁcient mouse.
2.5. Slc17a5−/− mice show a distinct spatiotemporal pattern of CNS
hypomyelination
In relation to the progressive downregulation of OL and myelin
marker genes during postnatal brain development, we investigated
age- and region-speciﬁc CNS myelination patterns in Slc17a5−/−mice.
In contrast to PNS observations, myelination of CNS nerve ﬁbers proved
obviously decreased in Slc17a5−/−mice. In Slc17a5+/+ brains from p18
mice, immunoﬂuorescence of the myelin constituent MBP labeled all
nerve tracts as is illustrated in Fig. 6 (A1, B1, C1). In Slc17a5−/− mice,
MBP staining was markedly decreased or even absent in nerve ﬁber
tracts in all investigated brain regions. The decreased and altered MBP
immunoreactivity in the CNS of Slc17a5−/−mice showed a prominent
difference between frontal brain regions and (ventral) hind brain/cere-
bellum (Fig. 6A2, B2, C2). The most affected cerebral regions include
corpus callosum(Fig. 6A2a-B2a) aswell as cingulum, internal and exter-
nal capsule andmost largewhitematter ﬁber tracts in the CNS.MBP im-
munoreactivity was nearly absent in cerebral cortex (Fig. 6A2b-B2b).
The remaining MBP-labeling, especially present in dorsal parts of
capsula, striatum and larger nerve ﬁbers was variable and had an aber-
rant clumpy and disorganized pattern in Slc17a5−/− mice brain (see
also Fig. 7).
To investigate the integrity of nerveﬁber axons, central brain regions
of Slc17a5+/+ and Slc17a5−/−mice were stained for neuroﬁlament (70
and 200 kDa). Data showed that axons were still present in most nerveﬁber tracts of Slc17a5−/−mice (not in anterior commissure, see Fig. 6A2,
Fig. 7). Globoid structures (Fig. 8 middle and lower panel) were present
in the affected white matter of cerebrum and cerebellum of Slc17a5−/−
mice and these showed strong neuroﬁlament immunoreactivity. Dou-
ble labeling immunoﬂuorescence staining of neuroﬁlament and MBP
showed clear engulfment of these axonal swellings by fragmented
MBP (Fig. 8 middle panel).
To gain further insight in temporal patterns of CNS myelination, we
investigatedmarkers of OL lineage cells in Slc17a5−/−mice brain during
themyelination period (Fig. 9A). We used three different markers of OL
lineage maturation and followed the myelination process through days
p2, p7 and p11 in Slc17a5+/+ and Slc17a5−/− mice. While O1 and O4
markers both stain immature OL, O4 is also a marker for late OPs
(Craig et al., 2003). MBP was used as a marker for myelinating, mature
OL.
Shortly after birth, the staining of OPs did not seem to be strikingly
different between Slc17a5+/+ and Slc17a5−/− mice, as shown by O4
staining at p2, and was mostly visible in ventral reticular brainstem re-
gions. In Slc17a5+/+ mice, the MBP, O4 and O1 staining progressively
diffused through p7 and p11 from the central white matter areas to ce-
rebral cortical areas, capsula interna and externa and corpus callosum.
However, while the pool of OPs as well as maturing OLs weakly in-
creased in brain of Slc17a5−/−mice, as seen by staining at p7 and p11
for the different OL lineage markers, it remained localized in central
brainstem areas and was weakly present in cerebellar white matter
(Fig. 9B).
2.6. Slc17a5−/− mice show progressive delay of neurobehavioral
development
Finally, we assessed neurobehavioral development of Slc17a5−/−
mice to characterize the functional consequences of the observed genet-
ic and pathological alterations. Achievement of developmental mile-
stones (Fig. 10) and performance level for some of these behaviors
(Fig. 11)was assessed fromp1 to p21. Earlymilestone behaviors include
negative geotaxis (turning the body head up when placed head down
Fig. 7. Decreased myelination but limited axonal loss in central brain regions of sialin-deﬁcient mice. Immunoﬂuorescence double labeling of MBP (red) and neuroﬁlament (green) in
internal capsular region of Slc17a5+/+ (WT, left) and Slc17a5−/− (KO, right) mouse brain at p18 (bregma−3.30, interaural 5.70 mm) (Paxinos and Watson, 1986). (Axon: green,
myelin sheet: red, blue: Hoechst nuclear counter stain). Scale bars: 50 μm. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version
of this article.)
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and surface righting (righting the body when placed on the back).
These behaviors reﬂect a postural reﬂex in response to altered body ori-
entation as well as physical strength and coordinated movement.
Slc17a5−/−mice showed similar performance to control littermates in
negative geotaxis and cliff aversion (Fig. 10; Fig. 11A–B). Milestone cri-
terion for surface righting was also reached at the same time (Fig. 10),
although performance speed was lower, especially during the ﬁrst peri-
natal and neonatal days (Fig. 11C;main effect of genotype; p b 0.01). All
later-stagemotor and sensorymilestones were signiﬁcantly retarded in
these mice (Fig. 10). Tactile ear twitch reﬂexes were delayed (p b 0.01),
while auditory startle responses were completely absent (p b 0.001).
Their weak appearance was illustrated by a delayed ability of forelimb
grasping (p b 0.05). Strong effects were also observed for the late post-
natal motor milestones of locomotion development (p b 0.001) and air
righting (righting the body after being held upside down and released;
p b 0.001). Time to exit the circle during the locomotion test was signif-
icantly higher in Slc17a5−/−mice (p b 0.001), although differenceswere
less pronounced for p8 (post-hoc p b 0.05), p9 (p b 0.01) and p16
(p b 0.05) (Fig. 11D; main effect of genotype, p b 0.001; interaction of
day and genotype, p b 0.05). Late-stage motor impairment was further
quantiﬁed using an open ﬁeld test at the age of 6–7 weeks. Comparing
Slc17a5−/− mice to Slc17a5+/+ littermates a signiﬁcant reduction in
both the distance traveled (2081 ± 561 cm versus 482 ± 524 cm;
p b 0.001) and rearing (35 ± 28 versus 2 ± 2; p b 0.05) was observed
in the Slc17a5−/−mutants.
3. Discussion
Sialin-deﬁcient mice were generated to study the pathophysiology
of clinical SASD (Prolo et al., 2009; Moechars et al., 2005). Sialin deﬁ-
ciency induced free sialic acid accumulation in these mice, and mim-
icked SASD-related leukoencephalopathy and clinical ISSD. Proton-
gradient mediated transport of glucuronic acid was deﬁcient in lyso-
somal vesicles from Slc17a5−/−mice, conﬁrming defective sialin-medi-
ated transport. Free sialic acid accumulated in cultured Slc17a5−/−
mouse ﬁbroblasts, and vacuolization with strong lysosomal marker
LAMP-1 immunoreactivity occurred in all examined tissues (including
CNS and PNS). These observations conﬁrm that Slc17a5−/−mice repro-
duce the basic pathogenic events of the human disorder. In the present
report, we examined the occurrence of pathognomonic genetic, histo-
pathological and behavioral anomalies in this putative ISSD model. An
overview of the overall set of ﬁndings can be found in Fig. 12.Hypomyelination is a typical pathological and neuroradiological
ﬁnding in brain of SASD patients (Haataja et al., 1994; Sonninen et al.,
1999; Varho et al., 2000; Parazzini et al., 2003; Morse et al., 2005;
Steenweg et al., 2010). Even inmildly affected Salla disease patients, ce-
rebral hypomyelination seems to be the most consistent abnormality,
observed already at the age of 3 to 6 months, well before the ﬁrst neu-
rological symptoms occur (Sonninen et al., 1999; Biancheri et al.,
2002). Severe hypomyelination in cerebral and cerebellar white matter
has been reported frombirth in ISSDpatients, consistentwith prenatally
arrested myelination (Parazzini et al., 2003). Hypomyelination appears
to be a consequence of insufﬁcient myelin deposition in sialin-deﬁcient
mice aswell. Brains of Slc17a5−/−micewere examined histologically at
an age at which the myelination process is still ongoing (p18). Strongly
reducedmyelin staining indicated defectivemyelination,which appears
related to a reduction of mature and possibly immature OLs. Microarray
analyses further indicated that, already at p10 andmarkedly at p18, ex-
pression of a wide variety of OL and myelin marker genes was reduced
in Slc17a5−/−mice, consistentwith a strong reduction ofmature OL. For
example,Myrf expression was unchanged at p0 but downregulated at
p10 and p18 in Slc17a5−/−mice. Notably, the transcription factorMyrf
is crucial for OL maturation and subsequent myelination processes
(Emery et al., 2009). It was shown to be decreased in the mouse
model for Niemann-Pick Type C1 disease (Yan et al., 2011), another ly-
sosomal storage disorder characterized by perturbed myelination.
In perinatal mice,Myrf expression by myelinating OLs is limited to the
spinal cord and posterior brain regions (Emery et al., 2009). This sup-
ports initial normal myelination in caudal CNS regions of Slc17a5−/−
mice.
Histological analysis at p18 indeed showed a gradient of OL density
with highest numbers in ventral hindbrain, followed by midbrain, and
forebrain SVZ, further decreasing in more distant areas.
Oligodendrogenesis is a late-stage process in brain development (El
Waly et al., 2014). Directed OPmigration and differentiation are still on-
going in theﬁrst postnatalweeks and are essential formyelin formation.
Immunohistochemistry indicated impaired colonization by immature
OPs (O1+ and O4+) and consequently mature OL (MBP+) during
later neonatal stages, whereas no obvious differences were observed
in central brainstem areas shortly after birth (p2). The reduced O4
distribution from posterior to rostral brain regions may suggest a
contribution of defective late OP migration to the observed
hypomyelination. Expression of early OL precursor markers such as
Pdgfra and Cspg4 did however not change during postnatal brain de-
velopment, in line with previous immunohistochemical ﬁndings
Fig. 8. Sialin-deﬁcient mice show neuroaxonal dystrophy characterized by axonal
swellings in the affected white matter. High magniﬁcation images (63×, 100×) of
Immunoﬂuorescence double labeling of MBP (red) and neuroﬁlament (green) in
cerebellum of Slc17a5+/+ (WT, upper panel) and Slc17a5−/− (KO, middle and lower
panel) mouse. (Axon: green, myelin sheet: red, blue: Hoechst nuclear counter stain;
arrow: axonal swelling). Scale bars: 20 μm. (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
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the OL lineage and transition to late OPs is accompanied by a
substantial reduction in migratory capacity (Warrington et al.,
1993; Barateiro and Fernandes, 2014). Notably, performance of a
neurosphere in vitro assay on neural stem cells of sialin-deﬁcient
mice could be an interesting suggestion for future research. This
could further elucidate the involvement of sialin in the different
steps of the generation of myelinating oligodendrocytes.
Likewise, microarray analyses at p0 could providemore information
on the early stages of pathogenesis. In contrast to the pronounced re-
duction in expression of myelin and OL marker genes at late develop-
mental stages, few genes were differentially expressed at p0.
Microarray analysis showed early upregulation and progressive differ-
ential expression of lysosomal genes, indicating changes in lysosomalstructure and function, probably in response to accumulating storage.
Increases in lysosomal size and number, and consequently also lyso-
somal proteins are commonobservations in lysosomal storage disorders
(Malone, 1976). In addition, a small subset of inﬂammatory genes was
already upregulated at this stage, suggesting an inﬂammatory response
that preceded reduced myelination. Substantially more inﬂammatory
genes became upregulated later in development, evident of progressive
neuroinﬂammation in sialin-deﬁcient mice. Progressive neuroinﬂam-
mation is frequently observed in lysosomal storage disorders and
could amplify hypomyelination by eliciting apoptosis (Fletcher et al.,
1812). Increased cell death and impaired downregulation of
polysialylated neural cell-adhesion molecule (PSA-NCAM) were ob-
served in optic nerves of Slc17a5−/− mice, and postulated to underlie
impaired myelination (Prolo et al., 2009). Developing oligodendrocytes
and late OPs in particular were shown to be increasingly vulnerable to
inﬂammatory and other insults (Back et al., 2002; Deng, 2010; Falahati
et al., 2013), suggesting a substantial contribution of neuroinﬂamma-
tion to the apparent defect of Slc17a5−/−mice in transition of early to
late OPs and more mature cells in the OL lineage.
In addition, we investigated the degree to which CNS
hypomyelination and leukoencephalopathy in Slc17a5−/−mice affected
their neurobehavioral performance. Slc17a5−/−mice seem to model
clinical ISSD, which is characterized by severe functional impair-
ments and developmental delays (Lemyre et al., 1999). At a rather
late stage of their disease, sialin-deﬁcient mice displayed reduced
ambulation in the open ﬁeld test, which might at least partly relate
to the gait abnormalities described in these mice (Prolo et al.,
2009). We did not observe any gross abnormalities in cerebellar
development, but focal axonal swellings were observed at p18
throughout the cerebellum, which are indicative for impaired axonal
transport and ﬁber degeneration (Prolo et al., 2009; Lovell and Jones,
1985; Kaartinen et al., 1996; Suzuki, 2003) and considered an impor-
tant factor in generating movement disorders in lysosomal storage
diseases (Walkley et al., 2010).
Slc17a5−/−mice showed a progressive delay of milestone achieve-
ment that paralleled the course of their leukoencephalopathy. They
showed timely achievement of early milestones (cliff aversion, negative
geotaxis and surface righting), whereas surface righting performance
was impaired. The righting reﬂex, which depends on vestibular system
and brainstem integrity, appears intact in Slc17a5−/−mice, but its exe-
cution could bemore difﬁcult depending on the postural adjustment re-
quired. Notably, myelination (especially in brainstem) was not severely
affected during the early perinatal days, but declined later on. Addition-
ally, these mice displayed severe delays in reaching the developmental
milestone of air righting, also reliant on labyrinthine function, but re-
quiring further maturation of the motor coordination system (Altman
and Sudarshan, 1975). In addition, Slc17a5−/− mice showed delayed
forelimb grasping as well as retarded transition from pivoting to
crawling, indicating delayed maturation of hindlimb use. Moreover,
they never reached the same level of straightforward locomotion as lit-
termate controls, typical of later developmental stages. By and large, the
aberrant neuromotor development in Slc17a5−/−mice seems toparallel
the spatiotemporal progression of their leukoencephalopathy,
supporting a causal role of defective myelinogenesis and central
hypomyelination in SASD-inducedmotor defects. Delayeddevelopment
of motor skills and/or ataxia are also typical in other human genetic
hypomyelination disorders such as Pelizaeus-Merzbacher disease
(Regis et al., 2008) and vanishing white matter disease (van der Lei et
al., 2010), as well as in animal models of central hypomyelination
such as shiverermutantmice (Lowet al., 2009). Notably, some function-
al impairments of sialin-deﬁcient mice, such as their delayed tactile ear
twitch reﬂex, could also be attributed to somatosensory defects. Also at
the sensory level, Slc17a5−/− mice developed no auditory startle re-
sponses during the measured timeframe. Auditory impairment indeed
appears to be another characteristic consequence of centralmyelination
defects. For example, delayed auditory evoked potentialswere observed
Fig. 9. Spatiotemporal differences in myelin and oligodendrocyte lineage marker expression during postnatal development in sialin-deﬁcient mice. (A) Overview images (10×
magniﬁcation) of mouse brain longitudinal sections from Slc17a5+/+ (WT) and Slc17a5−/− (KO) mice after immunoﬂuorescence staining for different markers of oligodendrocyte
progenitors (O4,O1) and mature myelinating oligodendrocytes (MBP) at postnatal stages p2, p7 and p11. Images represent planes corresponding to Paxinos and Watson (1986)
speciﬁed levels varying from lateral level 0.9 mm up to lateral level 1.90 mm. Background morphology is indicated in panel 6; (B) representative high magniﬁcation images of O4, O1
& MBP immunoﬂuorescence labeling at age p7. Red: O4-, O1- and MBP-labeling respectively. Blue: Hoechst nuclear counter stain. Scale bars: 50 μm; abbreviations: Bs: brainstem, Cb:
cerebellum, Cx: cortex, Hc: hippocampus, St: striatum. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 10. Progressive delay of reaching developmental milestones in sialin-deﬁcient mice.
Earliest neurobehavioral milestones (CA, SR, NG) are achieved at similar time points by
Slc17a5−/− mice (KO, white bars) in comparison to heterozygous and wildtype
littermates (grouped together as controls (CON), black bars). However they show a
progressive delay in reaching later milestones, with signiﬁcantly retarded achievements for
FG and ET and severe delays for LD, AR and AS. Data are presented as mean + SEM. Note:
plus-sign indicates that the milestone behavior AS was not exhibited by any of the
Slc17a5−/−mice during the observed period. Asterisks indicate signiﬁcance of difference in
comparison with control littermates (t-test; *p b 0.05, **p b 0.01, ***p b 0.001).
Abbreviations: CA, cliff aversion; SR, surface righting; NG, negative geotaxis; FG, forelimb
grasping; ET, ear twitch; LD, locomotion development; AR, air righting; AS, auditory startle.
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Jonquieres et al., 2014).
The present report links sialin deﬁciency to impaired OL lineage de-
velopment, and demonstrated that the resulting leukoencephalopathy
causes a distinct pattern of neurodevelopmental dysfunctions. In gener-
al, sialin deﬁciency clearly impairs the complex mechanisms of brain
myelination. Steps involved in the generation of oligodendrocytes and
myelin correlate to events of remyelination after myelin damage.
Studies in sialin knock-out mice could therefore also contribute to
pathophysiological and therapeutic research about more common
myelination disorders.4. Materials & methods
4.1. Slc17a5 knockout mice
Slc17a5 knockout mice were developed in collaboration with Lexi-
con Genetics Inc. and presented in 2005 (Moechars et al., 2005). Ani-
mals were maintained in an SPF facility that meets all Belgian and
European requirements for animal care. Mice were group-housed in a
climate-controlled animal colony with a 12 h dark-light cycle (light on
7:00 EST) with free access to food and water, except during behavioral
testing. Adequatemeasures were taken tominimize pain or discomfort.
All experiments were carried out in accordance with the European
Communities Council Directives (86/609/EEC) and were approved by
the local ethical committee.
Fig. 11. Decreased performance of milestone behaviors in sialin-deﬁcient mice. Slc17a5−/−mice (KO, white dots) show similar performance for milestone behaviors of cliff aversion and
negative geotaxis in comparison to control littermates (CON, black dots). These mice showed reduced performance for surface righting however (main effect of genotype p b 0.05). They
also showed increased exit latencies in the locomotion test, whichwere less pronouncedduringp8–9 and p16 (maineffect of genotype p b 0.001, day×genotype interaction p b 0.05). Data
are presented as mean + SEM.
116 S. Stroobants et al. / Experimental Neurology 291 (2017) 106–1194.2. Fibroblast isolation and free sialic acid measurement
Primary mouse embryonic ﬁbroblast (MEF) cultures were
established by standard procedures from individual embryonic day
13.5 (E13.5) embryos derived from heterozygous matings of
Slc17a5+/− mice. Permanent Slc17a5+/+, Slc17a5+/− and Slc17a5−/−
cell lines were established from transformed clones arising spontane-
ously after repeated passage in culture (Todaro et al., 1963). MEFs
were cultured in DMEM high glucose with L-glutamine, 10% FBS and
penicillin/streptomycin. When conﬂuent, cells were cryopreserved be-
fore sialic acid determination according to a modiﬁed thiobarbituric
acid test (Mancini et al., 1991). Free sialic acid values from Slc17a5+/+,
Slc17a5+/− and Slc17a5−/−MEFs are compared to the diagnostic values
of all clinical variants of SASD patients (infantile sialic acid storage dis-
ease (ISSD), intermediate SASD and Salla disease).
4.3. Biochemistry
In order to evaluate a defect of sialin function in Slc17a5−/−mice, the
proton driven uptake of a sialin-substrate was evaluated using rat liverlysosomal vesicles (RLV) as a reference.Mouse liverswere freshly dissect-
ed from 18 days old mice, either six Slc17a5−/−, six Slc17a5+/−, or six
Slc17a5+/+ mice, after overnight fasting. About 1.5 to 3 g wet weight
livers were obtained from each mouse group. Lysosomal membrane ves-
icles were prepared using a differential centrifugation method as de-
scribed (Mancini et al., 1989). Functional transport assays with
lysosomal membrane vesicles were performed as described for rat livers
with some adaptations as described for human lysosomalmembrane ves-
icles, using tritiated glucuronic acid as a substrate (Mancini et al., 1991).
4.4. Micro-array analysis
Total brain RNAwas isolated from newborn (p0) aswell as 10 (p10)
and 18 days (p18) old pups derived from heterozygous breeding pairs
using the RNeasy kit (Qiagen, Venlo, Netherlands) combined with
DNAse treatment. One microgram of extracted total RNA was biotin la-
beled and hybridized with the Mouse Genome 430 version 2.0
GeneChip array (Affymetrix, Orbassano, Italy). All data were processed
by using the statistical computing R-program(Rversion 2.4.0) (RDevel-
opment Core Team, URL www.R-project.org, 2006) and Bioconductor
Fig. 12. Overview of age-dependent pathological, genetic and behavioral alterations in sialin-deﬁcient mice characterized during the present study.
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the FARMS algorithm (Hochreiter et al., 2006). Grouping of the individ-
ual probes into gene-speciﬁc probe sets was performed based on the
Entrez Gene using the metadata package mm430mmentrezg (version
8). All analysis of themicroarray datawere done at three levels: spectral
map analysis (Wouters et al., 2003), signiﬁcance analysis of microarray
(SAM, at FDR b 0.005) (Tusher et al., 2001) and analysis of affected
processes.4.5. Tissue processing for histology
Five Homozygous Slc17a5−/− and ﬁve Slc17a5+/+ mice were
sacriﬁced by cervical dislocation and decapitation at p18. Brain tissue
and spinal cord were embedded in parafﬁn or cryopreservation in OCT
by freezing at −40 °C. To study the OL lineage, brain tissue of
Slc17a5−/− and Slc17a5+/+ mice at p2, p7 and p11 was processed in
the same way. Parafﬁn embedded material was sectioned at 6 μm
whereas cryopreserved samples were sectioned at 10 μm. Ischiadic
nerves were processed by plastic embedding.4.6. Histology
Routine morphological evaluation of all tissue sections was per-
formed on hematoxylin phloxin saffrane (HPS) stained sections and
Nissl stained sections for brain speciﬁc questions. Toluidine Blue stain-
ing was used to investigate peripheral nerve morphology.4.7. Immunohistochemistry
LAMP-1 (lysosomal associated membrane protein, isoform 1)
(Abcam, Cambridge, UK) (1/500) and GFAP (Dako Cytomation, 1/100)
stainingwas performed after heat-induced epitope retrieval and visual-
ized by Envision + System-HRP Labeled Polymer (Dako, Denmark),
followed by DAB.4.8. Immunoﬂuorescence techniques
All immunoﬂuorescence stains on deparafﬁnised sections required
an enzymatic pre-treatment of trypsin followed by heat mediated mi-
crowave antigen retrieval using EDTA. Immunohistochemistry on
10 μm thick cryosections required 4% paraformaldehyde ﬁxation prior
to incubation with the primary antibodies. Prior to incubation with
mouse monoclonal antibodies, blocking stages were performed using
10% normal goat serum (Dako, Denmark)with subsequent endogenous
mouse IgG blocking (Goat-anti-Mouse F'ab fragments, Jackson
Immunoresearch Laboratories, Inc., PA, USA). Mouse monoclonal anti-
bodies used are: anti-MBP (SMI-94, Abcam Ltd., Cambridge, UK) (1/
1000), anti-O1 and -O4 (Chemicon Int., CA USA) (1/100) and anti-neu-
roﬁlament proteins of 70- and 200-kDa (Euro-Diagnostica bv, Nether-
lands) (1/100). These monoclonal antibodies were visualized using
Cy3 conjugated goat anti-mouse IgG (Jackson Immunoresearch Labora-
tories, Inc., PA, USA) (1/500), Alexa555 conjugated goat anti-mouse IgM
(Invitrogen Corporate, Molecular Probes, California, USA) (1/500) or
Alexa488 conjugated goat anti-mouse IgG (Invitrogen Corporate, Mo-
lecular Probes, California, USA) (1/100) depending on the application.
Rabbit polyclonal antibodies used are anti-GFAP (Dako Cytomation)
(1/100) and anti-MBP (Abcam Ltd., Cambridge, UK) (1/100). These are
visualized by Cy3 conjugated goat anti-rabbit IgG (Jackson
Immunoresearch Laboratories, Inc., PA, USA) (1/500) or Alexa488 con-
jugated goat anti-rabbit IgG (Invitrogen Corporate, Molecular Probes,
California, USA) (1/100) depending on the application. All sections
were counterstained with Hoechst (Invitrogen Corporate, Molecular
Probes, California, USA) (1/500).
4.9. Imaging and analysis
Imaging was performed on Axioplan-2 Imaging microscope (Carl
Zeiss, Germany) equipped with a high resolution Axiocam camera and
the Multidimensional and Mosaics modules of the imaging software
Axiovision Release 4.6. Quantitative analysis of the number of cortical
neuronal and non-neuronal cells and of cerebellar Purkinje cells was
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5 Slc17a5−/− and Slc17a5+/+ mouse brains at P18. The 10 regions ana-
lyzed were randomly chosen throughout the entire cortex and Purkinje
cell layer. One region corresponds to 0.096 mm2 using a 63× objective
and eyepiece with ﬁeld number 22. Results were analyzed by a non-
parametrical Wilcoxon Krüskal-Wallis test.
4.10. Neurobehavioral development
Developmental milestones were daily evaluated in neonatal mice of
all genotypes (p1–p21). No obvious differenceswere observed between
heterozygous and wildtype mice, hence they were compared as one
control group (n = 38) to performance of sialin knockout mice (n =
11). The developmental test battery (adapted from (Hill et al., 2008))
involved assessment of milestone achievement and speed of execution
of milestone behaviors. Speciﬁcally, the following behaviors were ex-
amined during the relevant period of age: surface righting (time for a
pup to turn over after being held on its back; max 30 s – milestone cri-
terion 1 s); negative geotaxis (time for a pup to turn after being placed
head-down on a 45° slope; max 30 s – milestone criterion b10 s); cliff
aversion (time for a pup, placed at the edge of a plastic box, to turn
away from the edge; max 30 s – milestone criterion b10 s); forelimb
grasping (ability of a pup to grip a thin bar with its forepaws; milestone
criterion 1 s); locomotion development (time for a pup to exit a 13-cm
diameter circle;max 30 s –milestone criterion b10 s); air righting (abil-
ity of a pup, after being held upside down and released at ~11 cmheight,
to turn and land on all paws). Sensory developmentalmarkerswere also
evaluated: auditory startle (appearance of a startle response to a
handclap at ~10 cm); ear twitch (appearance of ear twitching after tac-
tile stimulation with a cotton swab tip). If the milestone behavior was
not exhibited during the observed time period, milestone achievement
was quantiﬁed as ‘last day of testing + 1’. Data were analyzed using t-
tests (for milestone achievement data) and repeated-measures
ANOVA (for performance data).
4.11. Open ﬁeld test
A panel of eight Slc17a5+/+, eight Slc17a5+/− and ﬁve Slc17a5−/−,
aged between six and seven weeks were subjected to the OFT, which
was performed during the light phase of a normal light/dark cycle. A
large arena (40 cm × 40 cm) with infrared beams at three different
levels was used to record rearing and locomotor activity. The animal
was placed in the center and its activity was measured for 20 min.
Data from this test were analyzed in ﬁve, 4-minute intervals. The total
distance traveled (cm) and vertical movement number (rearing) were
recorded. Data were analyzed using a t-test.
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